1. Home
  2. SWVL vs CTMX Comparison

SWVL vs CTMX Comparison

Compare SWVL & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Swvl Holdings Corp

SWVL

Swvl Holdings Corp

HOLD

Current Price

$2.30

Market Cap

30.1M

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$4.16

Market Cap

596.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWVL
CTMX
Founded
2017
2008
Country
United Arab Emirates
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.1M
596.2M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
SWVL
CTMX
Price
$2.30
$4.16
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$6.50
AVG Volume (30 Days)
7.6K
2.0M
Earning Date
09-08-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.22
EPS
N/A
0.24
Revenue
$19,329,423.00
$113,631,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$17.32
Revenue Growth
N/A
N/A
52 Week Low
$2.10
$0.40
52 Week High
$7.20
$4.62

Technical Indicators

Market Signals
Indicator
SWVL
CTMX
Relative Strength Index (RSI) 33.03 57.36
Support Level $2.20 $3.78
Resistance Level $2.60 $4.20
Average True Range (ATR) 0.20 0.24
MACD -0.04 -0.02
Stochastic Oscillator 22.50 73.88

Price Performance

Historical Comparison
SWVL
CTMX

About SWVL Swvl Holdings Corp

Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: